The Therapeutic Goods Administration, Australia’s regulatory agency for medical drugs and devices, approved BioMimetic’s application based on data from the company’s clinical trials in North America.

BioMimetic, a Franklin-based medical products maker, expects a full launch of Augment in Australia by next spring.

Augment is being marketed as an alternative to autograft; the current standard bone grafting technique used in hindfoot and ankle fusion procedures.

BioMimetic has approval for Augment in Canada. Decisions on approval are pending in the United States and Europe from the U.S. Food and Drug Administration and European Union.